|Awarded On||August 21, 2019|
|Title||Dissecting cellular heterogeneity of bulk tumors for prediction of overall survival and responsive patients to immunotherapy|
|Award Mechanism||Individual Investigator Research Awards for Computational Biology|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Tao Wang|
|Cancer Sites||Kidney and Renal Pelvis|
RCCs affect a wide range of demographics in the U.S. At the time of diagnosis, ~30% of RCC patients already have metastatic disease and ~30% of patients will recur. 5-year survival for patients who recur is smaller than 10%. Although immunotherapy is transforming cancer care, the response rate is only ~25%, and it’s still unclear how to distinguish responsive patients. The stroma/immune cellular components are critical for immunotherapy response and prognosis in RCC patients. Therefore, it is essential to accurately characterize tumor immunity responses in RCC on the genome-wide scale. We propose to first dissect bulk tumor expression into the tumor cell, normal parenchyma, and tumor stroma/...